Therapeutic Advances in Advanced Basal Cell Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 14

PMID 39272933

Authors

Samer Alkassis

Maya Shatta

Deborah J Wong

Affiliations

Soon will be listed here.

Abstract

Basal cell carcinoma (BCC) is the most common type of cancer with an estimated 3.6 million cases diagnosed annually in the US alone. While most cases are treatable with low recurrence rates, 1-10% progress to an advanced stage which can behave aggressively, leading to local destruction and posing substantial challenges in management. The pathogenesis often involves dysregulation of the patched/hedgehog protein family, a pivotal pathway targeted by recently approved therapies. Furthermore, the role of immunotherapy is evolving in this type of tumor as we learn more about tumor microenvironment dynamics. In recent years, there have been advancements in the therapeutic landscape of advanced BCC, offering patients new hope and options for managing this complex and potentially life-threatening condition. In this review, we aim to provide a comprehensive overview of this disease, including the risk factors, underlying pathogenesis, current treatment options of advanced disease, and the ongoing exploration and development of novel therapies.

References

Brash D, Rudolph J, Simon J, Lin A, McKenna G, Baden H . A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991; 88(22):10124-8. PMC: 52880. DOI: 10.1073/pnas.88.22.10124. View

Lear J, Migden M, Lewis K, Chang A, Guminski A, Gutzmer R . Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2017; 32(3):372-381. PMC: 5873455. DOI: 10.1111/jdv.14542. View

Mohan S, Chang A . Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma. Clin Cancer Res. 2015; 21(12):2677-83. DOI: 10.1158/1078-0432.CCR-14-3180. View

Camela E, Ilut Anca P, Lallas K, Papageorgiou C, Manoli S, Gkentsidi T . Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes. Medicina (Kaunas). 2023; 59(2). PMC: 9964036. DOI: 10.3390/medicina59020349. View

Marzuka A, Book S . Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015; 88(2):167-79. PMC: 4445438. View

Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V . Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016; 48(4):398-406. DOI: 10.1038/ng.3525. View

Gao J, Shi L, Zhao H, Chen J, Xiong L, He Q . Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016; 167(2):397-404.e9. PMC: 5088716. DOI: 10.1016/j.cell.2016.08.069. View

Altaraihi M, Wadt K, Ek J, Gerdes A, Ostergaard E . A healthy individual with a homozygous frameshift variant: Are variants of associated with nevoid basal cell carcinoma syndrome?. Hum Genome Var. 2019; 6:10. PMC: 6384928. DOI: 10.1038/s41439-019-0041-2. View

Mohan S, Chang A . Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr Dermatol Rep. 2014; 3:40-45. PMC: 3931971. DOI: 10.1007/s13671-014-0069-y. View

10.

Dummer R, Guminksi A, Gutzmer R, Lear J, Lewis K, Chang A . Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2019; 182(6):1369-1378. PMC: 7318253. DOI: 10.1111/bjd.18552. View

11.

Snaidr V, Damian D, Halliday G . Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019; 28 Suppl 1:15-22. DOI: 10.1111/exd.13819. View

12.

Boaventura P, Pereira D, Mendes A, Batista R, Ferreira da Silva A, Guimaraes I . Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. J Dermatol Sci. 2013; 73(1):31-9. DOI: 10.1016/j.jdermsci.2013.09.002. View

13.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

14.

Fania L, Mazzanti C, Campione E, Candi E, Abeni D, Dellambra E . Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. Int J Mol Sci. 2019; 20(23). PMC: 6929077. DOI: 10.3390/ijms20235946. View

15.

Kilgour J, Jia J, Sarin K . Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. Cancers (Basel). 2021; 13(15). PMC: 8345475. DOI: 10.3390/cancers13153870. View

16.

Chiang E, Stafford H, Buell J, Ramesh U, Amit M, Nagarajan P . Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma. Cancers (Basel). 2023; 15(9). PMC: 10177565. DOI: 10.3390/cancers15092453. View

17.

Morgan F, Ruiz E, Karia P, Besaw R, Neel V, Schmults C . Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. J Am Acad Dermatol. 2021; 85(3):582-587. DOI: 10.1016/j.jaad.2021.01.052. View

18.

Walter A, Barysch M, Behnke S, Dziunycz P, Schmid B, Ritter E . Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res. 2010; 16(14):3562-70. DOI: 10.1158/1078-0432.CCR-09-3136. View

19.

Zelin E, Maronese C, Dri A, Toffoli L, Di Meo N, Nazzaro G . Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. J Clin Med. 2022; 11(12). PMC: 9225110. DOI: 10.3390/jcm11123364. View

20.

Deutsch J, Lai J, Schenk K, Soni A, Will E, Engle L . Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade. J Immunother Cancer. 2023; 11(12). PMC: 10729066. DOI: 10.1136/jitc-2023-007463. View